SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Authors:
- Robert P. LyonRLRobert P. Lyon
- Mechthild JonasMJMechthild Jonas
- Christopher FrantzCFChristopher Frantz
- Esther S. TruebloodETEsther S. Trueblood
- Roma YumulRYRoma Yumul
- Lori WestendorfLWLori Westendorf
- Christopher J. HaleCHChristopher J. Hale
- Jackie L. StilwellJSJackie L. Stilwell
- Narayana YeddulaNYNarayana Yeddula
- Katie M. SneadKSKatie M. Snead
- Vineet KumarVKVineet Kumar
- Gabriela I. Patilea-VranaGPGabriela I. Patilea-Vrana
Open Access
- 24 August 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (12) , 1444-1453
Abstract
Integrin beta-6, a component of the heterodimeric adhesion receptor alpha-v/beta-6, is overexpressed in numerous solid tumors. Its expression has been shown by multiple investigators to be a negative prognostic indicator in diverse cancers including colorectal, non–small cell lung, gastric, and cervical. We developed SGN-B6A as an antibody–drug conjugate (ADC) directed to integrin beta-6 to deliver the clinically validated payload monomethyl auristatin E (MMAE) to cancer cells. The antibody component of SGN-B6A is specific for integrin beta-6 and does not bind other alpha-v family members. In preclinical studies, this ADC has demonstrated activity in vivo in models derived from non–small cell lung, pancreatic, pharyngeal, and bladder carcinomas spanning a range of antigen expression levels. In nonclinical toxicology studies in cynomolgus monkeys, doses of up to 5 mg/kg weekly for four doses or 6 mg/kg every 3 weeks for two doses were tolerated. Hematologic toxicities typical of MMAE ADCs were dose limiting, and no significant target-mediated toxicity was observed. A phase I first-in-human study is in progress to evaluate the safety and antitumor activity of SGN-B6A in a variety of solid tumors known to express integrin beta-6 (NCT04389632).Keywords
All Related Versions
Funding Information
- N/A
This publication has 48 references indexed in Scilit:
- The Pharmacologic Basis for Antibody-Auristatin Conjugate ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- αvβ6 Integrin Promotes the Invasion of Morphoeic Basal Cell Carcinoma through Stromal ModulationCancer Research, 2008
- Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survivalThe Journal of Pathology, 2007
- Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid TumorsClinical Cancer Research, 2007
- Alpha-v Integrins as Therapeutic Targets in OncologyCancer Investigation, 2007
- Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue BindingClinical Cancer Research, 2005
- Switch from αvβ5 to αvβ6 integrin expression protects squamous cell carcinomas from anoikisJournal of Cell Biology, 2004
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityBlood, 2003
- Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues.Journal of Histochemistry & Cytochemistry, 1993